RxDoctor Payments Data

Sally Dowling, MD

Family Medicine · Selbyville, DENPI 1922005255

Payments from drug & device makers

$410in general payments, 2019–2025

Across 15 payments — averaging $27.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$137
  • Abbott$83
  • Novo Nordisk$75
  • GSK$36
  • AbbVie$28
  • Lilly USA, LLC$23
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$410 in reported general payments places this provider in the 55th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$197,551
Medicare patients
350
Services billed
3,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$62,804
OzempicSemaglutide29$55,777
JanuviaSitagliptin Phosphate43$49,640
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$26,380
JardianceEmpagliflozin24$25,071
ViberziEluxadoline13$21,401
Spiriva RespimatTiotropium Bromide13$10,687
MyrbetriqMirabegron11$5,556
Losartan Potassium322$5,313
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$4,836
Metoprolol Succinate233$4,406
Pantoprazole Sodium215$3,722
Levothyroxine Sodium271$3,639
Potassium Chloride65$3,538
Atorvastatin Calcium229$2,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$75$55,77729 claims
GSKTrelegy Ellipta, Anoro Ellipta$36$31,21646 claims
AbbVieViberzi$28$21,40113 claims
Astellas Pharma US IncMyrbetriq$14$5,55611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 352 family medicine providers in Delaware.

Other family medicine in Selbyville

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →